目的 探讨临床药师在下肢深静脉血栓形成合并肺结核患者个体化抗凝治疗方案的制订，新型口服抗凝药的选择、用药监护中的工作要点。方法 参与1例下肢深静脉血栓合并肺结核患者的抗凝治疗用药方案的制订与用药监护。该患者既往服用华法林但不起效，临床药师从基因多态性、药物相互作用等方面寻找原因，重新为患者制订给药方案。结果 确定适合患者的给药方案，患者抗凝达标后出院，临床药师从影响华法林疗效的各种因素，INR的监测等注意事项对患者进行用药教育，提高患者抗凝治疗依从性。结论 抗凝药物个体化给药方案的制订和用药监护是临床药师开展药学服务的工作切入点。
Abstract
OBJECTIVE To find out the essentials of clinical pharmacists’ work on making individualized anticoagulation therapy, tailored to patients with deep vein thrombosis and pulmonary tuberculosis, and on its pharmaceutical care. METHODS The clinical pharmacist participated in one case of individualized anticoagulation therapy and provided pharmaceutical care to one patient with deep vein thrombosis and pulmonary tuberculosis. The patient used to take warfarin, but the treatment was ineffective, therefore the clinical pharmacist tried to find out the reason from such aspects as interactions among genetic polymorphism, anticoagulants and anti-TB drugs, then adjusted the therapy for the patient. RESULTS A dosage regimen suitable for the patient was formulated, and medication education was carried out to the patient in terms of medication instructions, such as influencing factors on curative effects of warfarin and monitoring of INR, to improve the patient compliance related to anticoagulation therapy. CONCLUSION Clinical pharmacists should start pharmaceutical service right from making individualized anticoagulation therapy and carrying out pharmaceutical care.
关键词
抗凝药物 /
华法林 /
利伐沙班 /
抗结核药物 /
药学监护
{{custom_keyword}} /
Key words
anticoagulate drugs /
warfarin /
rivaroxaban /
anti-TB drugs /
pharmaceutical care
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] GIUNTINI C, RICCO D G, MARINI C, et al. Pulmonary embolism: epidemiology . Chest, 1995, 107(suppl 1):3-9.
[2] CHINESE ANTITUBERCULOSIS ASSOCIATION. Guidline for chemotherapy of drug resistant TB(2015). J Chin Antitiberc Assoc(中国防痨杂志),2015,37(5):421-469.
[3] DEPARTMENT OF DISEASE CONTROL, MOH, DEPARTMENT OF MEDICAL ADMINISTRATION, MOH, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION. Guidelines for Implementing the National Tuberculosis Control Program in China(2008)(中国结核病防治规划实施工作指南). Vol 2. Beijing:Pecking Union Medical College Press, 2008,3.
[4] GUYATT G H, AKL E A, CROWTHER M, et al. Executive summary:Antithrombotic Therapy and Prevention of Thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012,141(suppl 2):7S-47S.
[5] JONAS D E, MCLEOD H L. Genetic and clinical factors relation to warfarin dosing. Trends Pharmacol Sci, 2009, 30(7):375-386.
[6] LAL S, JADA S R, XIANG X, et al. Pharmacogenetics of target gens across the warfarin pharmacological pathway. Clin Pharmacokinet, 2006, 45(12):1189-1200.
[7] MATAGRIN B, HODROGE A, MONTAGUT-ROMANS A, et al. New insights into the catalytic mechanism of vitamin K epoxide reductase (VKORC1)-The catalytic properties of the major mutations of VKORC1 explain the biological cost associated to mutations. FEBS Open Bio,2013,3:144-150.
[8] GAIKWAD T, GHOSH K, KULKARNI B, et al. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population . Eur J Pharmacol,2013,710(1-3):80-84.
[9] SHALIA K K, DOSHI S M, PARIKH S, et al. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response. J Assoc Physicians India, 2012,60:34-38.
SHUEN A Y, WONG B Y, FU L, et al. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic . Clin Biochem,2012,45(6):397-401.
MASUR H, BROOKS J T, BENSON C A, et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis,2014,58(9):1308-1311.
MINISTRY OF HEALTH MALAYSIA, ACADEMY OF MEDICINE MALAYSIA, MALAYSIAN THORACIC SOCIETY. Management of Tuberculosis. 3rd ed. Putrajaya: Malyaysia Health Technology Assessment Section,2012:42-47.
LUNG ASSIOCIATION’S TUBERCULOSIS COMMITTEE. Tuberculosis information for health care providers. 4th ed. Ontario, Canada:Ontario Lung Association,2009:19. http://www. on. lung. ca/Document. Doc?id=475.
YATES S, SARODE R. Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects. Curr Opin Hematol, 2013,20(6):552-557.
PFEILSCHIFTER W, LUGER S, BRUNKHORST R, et al. The gap between trial data and clinical practice—an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc Dis, 2013,36(2):115-119.
POZNIAK A L, COYNE K M, MILLER R F, et al. British HIV association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med, 2011,12(9):517-524.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家自然科学基金资助项目(81273592,81202592,81573504)
{{custom_fund}}
PDF(649 KB)
